Desidustat (BioDeep_00000178103)
human metabolite blood metabolite
代谢物信息卡片
化学式: C16H16N2O6 (332.1008316)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC1CON2C3=CC=CC=C3C(=C(C2=O)C(=O)NCC(=O)O)O
InChI: InChI=1S/C16H16N2O6/c19-12(20)7-17-15(22)13-14(21)10-3-1-2-4-11(10)18(16(13)23)24-8-9-5-6-9/h1-4,9,21H,5-8H2,(H,17,22)(H,19,20)
描述信息
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C78275 - Agent Affecting Blood or Body Fluid
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Desidustat is an orally active HIF hydroxylase inhibitor. Desidustat can be used for the research of various disorders including anemia of different types and conditions associated with ischemia/hypoxia[1].
同义名列表
7 个代谢物同义名
2-{[1-(cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinolin-3-yl]formamido}acetic acid; 2-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido)acetic acid; N-(1-(Cyclopropylmethoxy)-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine; {[1-(cyclopropylmethoxy)-4-hydroxy-2-oxoquinolin-3-yl]formamido}acetic acid; ZYAN1 compound; Desidustat; ZYAN1
数据库引用编号
7 个数据库交叉引用编号
- PubChem: 75593290
- HMDB: HMDB0251046
- ChEMBL: CHEMBL4650314
- Wikipedia: Desidustat
- chemspider: 64835241
- CAS: 1616690-16-4
- medchemexpress: HY-103227
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Sishir Gang, Prakash Khetan, Deepak Varade, Venkata Ramakrishna Chinta, Siddharth Mavani, Umesh Gupta, S Venkata Krishna Reddy, Sunil Rajanna, Tarun Jeloka, Vivek Ruhela, Kevinkumar Kansagra, Pooja Kanani, Jayesh Bhatt, Kuldipsinh Zala. Desidustat in Anemia due to Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-D).
American journal of nephrology.
2022; 53(5):343-351. doi:
10.1159/000523949. [PMID: 35462369] - Dhananjai Agrawal, Deepak Varade, Hardik Shah, Alm Nazar, Jayakumar Krishnan, Vineet Shukla, Chinta Ramakrishna, Mahel Chinthana Bandara Galahitiyawa, Sidhharth B Mavani, Sunil Rajanna, Petkar Jikki, Shamila De Silva, Vivek Ruhela, Parshottam Koradia, Kevinkumar Kansagra, Pooja Kanani, Nitin Sharma, Kuldipsinh Zala, Deven Parmar. Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND).
American journal of nephrology.
2022; 53(5):352-360. doi:
10.1159/000523961. [PMID: 35462372] - Amit A Joharapurkar, Vishal J Patel, Samadhan G Kshirsagar, Maulik S Patel, Hardikkumar H Savsani, Mukul R Jain. Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress.
Drug development research.
2021 09; 82(6):852-860. doi:
10.1002/ddr.21792. [PMID: 33480036] - Mukul Jain, Amit Joharapurkar, Vishal Patel, Samadhan Kshirsagar, Brijesh Sutariya, Maulik Patel, Hiren Patel, Pankaj R Patel. Pharmacological inhibition of prolyl hydroxylase protects against inflammation-induced anemia via efficient erythropoiesis and hepcidin downregulation.
European journal of pharmacology.
2019 Jan; 843(?):113-120. doi:
10.1016/j.ejphar.2018.11.023. [PMID: 30458168] - Deven V Parmar, Kevinkumar A Kansagra, Jatin C Patel, Shuchi N Joshi, Nitin S Sharma, Apeksha D Shelat, Nirav B Patel, Vishal B Nakrani, Farheen A Shaikh, Harilal V Patel. Outcomes of Desidustat Treatment in People with Anemia and Chronic Kidney Disease: A Phase 2 Study.
American journal of nephrology.
2019; 49(6):470-478. doi:
10.1159/000500232. [PMID: 31112954] - Kevinkumar A Kansagra, Deven Parmar, Rajendra H Jani, Nuggehally R Srinivas, Jason Lickliter, Harilal V Patel, Devang P Parikh, Heather Heading, Hardik B Patel, Rahul J Gupta, Chintan Y Shah, Maulik R Patel, Vyom N Dholakia, Raghav Sukhadiya, Mukul R Jain, Krupi V Parmar, Kinjal Barot. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
Clinical pharmacokinetics.
2018 01; 57(1):87-102. doi:
10.1007/s40262-017-0551-3. [PMID: 28508936] - Harilal Patel, Amit Arvind Joharapurkar, Vrajesh Bhaskarbhai Pandya, Vishal Jagjivanbhai Patel, Samadhan Govind Kshirsagar, Prakash Patel, Bhavesh Gevriya, Mukul R Jain, Nuggehally R Srinivas, Pankaj Ramanbhai Patel, Ranjit C Desai. Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Jan; 48(1):37-44. doi:
10.1080/00498254.2016.1278287. [PMID: 28042744] - Harilal Patel, Krunal Soni, Rucha Trivedi, Heather Heading, Jason Geue, Kevinkumar Kansagra, Rahul J Gupta, Vrajesh B Pandya, Nuggehally R Srinivas, Pankaj R Patel, Ranjit C Desai. A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC-MS/MS electrospray ionization.
Bioanalysis.
2017 May; 9(9):719-732. doi:
10.4155/bio-2017-0014. [PMID: 28488896]